← Back to patent-cliff list
Eravacycline
Tier C — Watch / tradeEravacycline · all drugs expiring in 2030 →
Som Biotech Sl
Originator
-
First approval
2030
Expiry (public)
$0.1B *
Peak sales
Small molecule
Type
Targets：30S subunit, 3CLp, Peptide hydrolase
Indications (approved)：COVID-19
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Eravacycline?
Approved indications include: COVID-19.
When does the Eravacycline patent expire?
Based on public sources, the Eravacycline patent expires in 2030.
How do I get a quote for Eravacycline intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29